Recommendation Updates

Follow the latest news on active Turnaround Letter purchase recommendations.

Large Cap / Pharmaceuticals, Biotechnology & Life Sciences

Bristol-Myers Financials Announced

On January 26, 2012, Bristol-Myers Squibb Company (NYSE: BMY) announced financial results for the fourth quarter of 2011. Bristol-Myers Squibb posted fourth quarter 2011 net sales of $5.5 billion, an increase of 7% compared to the same period a year ago. U.S. net sales increased 8% to $3.6 billion in the quarter compared to the same period a year ago, and international net sales increased 4% to $1.9 billion. The Company reported net earnings attributable to Bristol-Myers Squibb of $852 million, or $0.50 per share, in the quarter compared to $483 million, or $0.28 per share, a year ago. The incremental impact in 2011 over 2010 of the two additional U.S. health care reform provisions for new discounts associated with the Medicare Part D coverage gap and the annual pharmaceutical company fee decreased fourth-quarter EPS by approximately $0.04. Cash, cash equivalents and marketable securities were $11.6 billion, with a net cash position of $6.2 billion, as of December 31, 2011. Bristol-Myers Squibb is setting its 2012 GAAP and non-GAAP EPS guidance range from $1.90 to $2.00. Both GAAP and non-GAAP guidance assume current exchange rates.

Read More Purchase Recommendation Updates

Identify & Profit from Distressed Investing

Free Report: Turnaround Investing Mistakes

Turnaround Investing Blog

Turnaround Investing Blog

Is there value in bankrupt PG&E’s stock?

In nearly every case, the shares of a company in bankruptcy become worthless. In very rare cases, however, they can become great investments. W.R. Grace (NYSE:GRA) shares produced a 75-fold return, as an example. With California utility PG&E (NYSE:PCG) now in bankruptcy, the range of possible outcomes for its equity is wide.

Read More.

EV/EBITDA: What Is It & Why Are We Using It More?

In reading recent editions of The Turnaround Letter, you have probably noticed that we are increasingly using EV/EBITDA as a valuation measure, rather than the better-known price/earnings multiple.  We thought it might be useful to describe this measure and why we like it.

Read More.

Turnaround Letter Stock Pick Named Top Performer of 2017


stock market advicex


What Last Year's Top Stock Pickers Are Buying in 2018


This Forbes write-up follows up on the recent Top Stock Tips report--naming The Turnaround Letter's Crocs recommendation the top performer of 2017: With 90% gains, CROX beat out 100 other investment ideas included in the report; and the stock continues to have value investing appeal, according to Putnam.


George notes, "We see additional upside for the stock in 2018 as management's efforts continue to bear fruit, though the gains will likely be more muted than we saw in 2017."